



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re Application of

**BIGOT, et. al.**

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

Application No.: **10/608,689**

Filed: **June 27, 2003**

Title: **NOVEL ADENOSINE ANALOGUES AND THEIR  
USE AS PHARMACEUTICAL AGENTS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 14, 2005  
Date of Deposit

Brian Pritchett  
Signature

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,




Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2002/0059 US NP

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



|                             |                         |
|-----------------------------|-------------------------|
| <b>Application Number</b>   | 10/608,689              |
| <b>Filing Date</b>          | 06-27-2003              |
| <b>First Named Inventor</b> | BIGOT, et. al.          |
| Group Art Unit              | Not Yet Assigned        |
| Examiner Name               | Not Yet Assigned        |
| Attorney Docket Number      | DEAV2002/0059 - US - NP |

|       |   |    |   |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

[illegible][illegible]

|            |  |
|------------|--|
| Date       |  |
| Considered |  |

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+

☒

+

Substitute for form 1449B/PTO

**Complete if Known**

(use as many sheets as necessary)

Sheet

2

of

2

**Application Number**

10/608.689

Filing Date

06-27-2003

**First Named Inventor**

BIGOT, et. al.

Group Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

DEAV2002/0059 - US - NP

[illegible]

Examiner  
Signature

Date \_\_\_\_\_

Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+